ClinicalTrials.gg
CompletedNCT00943852Updated Feb 9, 2022Results posted

The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)

A Phase 1 interventional study of losartan potassium and Comparator: isosorbide mononitrate (ISMN) in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
58th of 65
13 · median 100
Started
2006
with 2 others
Phase 1
9 of 65
1 open now
Registered
24th of 65
by date
Lead sponsor
7 of 65
Organon and Co

Among the 65 studies testing losartan in Hypertension, this one is the 58th largest by enrollment, is one of 3 that started in 2006, is one of 9 in phase 1, and was the 24th registered.

Hypertension

6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 45 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

This study will qualify a functional model that can measure central blood pressure and vascular compliance effects through noninvasive means.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is in good health with the exception of mild to moderate hypertension
  • Patient is willing to comply with the study restrictions
  • Patient does not smoke

Exclusion criteria

Exclusion Criteria:

  • Patient has a history of any illness that might confound the results of the study or make participation in the study unsafe
  • Patient is taking a prescription medication that is for use with COZAAR® or IMDUR®
  • Patient has a condition for which there is a warning, contraindication, or precaution against the use of COZAAR® or IMDUR®
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    1

    losartan 100 mg

    Drug: losartan potassium

  • Active comparator
    2

    ISMN 60 mg

    Drug: Comparator: isosorbide mononitrate (ISMN)

  • Active comparator
    3

    losartan 100 mg + ISMN 15 mg

    Drug: Comparator: losartan + ISMN

  • Active comparator
    4

    losartan 100 mg + ISMN 60 mg

    Drug: Comparator: losartan + ISMN

  • Placebo comparator
    5

    Placebo

    Drug: Comparator: Placebo

Interventions

  • Single dose losartan 100 mg in one of five treatment periods

    Also known as: COZAAR

  • Single dose ISMN 60 mg in one of five treatment periods

    Also known as: IMDUR

  • DrugComparator: losartan + ISMN

    Drug pages: Losartan · Isosorbide mononitrate

    Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods

  • DrugComparator: losartan + ISMN

    Drug pages: Losartan · Isosorbide mononitrate

    Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods

  • DrugComparator: Placebo

    Single dose placebo only in one of five treatment periods

06

What researchers measure

Primary outcomes

  1. Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg

    The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.

    Time frame: Baseline and 10 hours postdose

  2. Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo

    The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.

    Time frame: Baseline and 10 hours postdose

07

Results

Posted Jul 15, 2010
Limitations and caveats
Due to lower than expected Blood Pressure's in individual patients, an interim analysis was undertaken after 11 patients had completed 3 to 5 of the study periods; enough data was already collected to meet objectives, so the trial was stopped early.

Participant flow

First Patient Entered: 31-Aug-2006 Last Patient Last Visit: 11-Dec-2006 Number of Sites: 1

First Period of Treatment Intervention
Participant flow — First Period of Treatment Intervention
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2112112111
Completed2112112111
Not completed0000000000
Washout Period After Period 1 Treatment
Participant flow — Washout Period After Period 1 Treatment
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2112112111
Completed2111112111
Not completed0001000000
Withdrew: Bp too low for dosing at the next period0001000000
Second Period of Treatment Intervention
Participant flow — Second Period of Treatment Intervention
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2111112111
Completed2111112111
Not completed0000000000
Washout Period After Period 2 Treatment
Participant flow — Washout Period After Period 2 Treatment
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2111112111
Completed2111102111
Not completed0000010000
Withdrew: Trial stopped early0000010000
Third Period of Treatment Intervention
Participant flow — Third Period of Treatment Intervention
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2111102111
Completed2111102111
Not completed0000000000
Washout Period After Period 3 Treatment
Participant flow — Washout Period After Period 3 Treatment
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2111102111
Completed2111101111
Not completed0000001000
Withdrew: Did not meet criteria for next period0000001000
Fourth Period of Treatment Intervention
Participant flow — Fourth Period of Treatment Intervention
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2111101111
Completed2111101111
Not completed0000000000
Washout Period After Period 4 Treatment
Participant flow — Washout Period After Period 4 Treatment
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started2111101111
Completed1100100011
Not completed1011001100
Withdrew: Not taking medication per protocol0000000100
Withdrew: Trial stopped early1011001000
Fifth Period of Treatment Intervention
Participant flow — Fifth Period of Treatment Intervention
MilestonePlacebo / Losartan / Losartan + ISMN / Losartan + ISMN / ISMNLosartan / ISMN / Losartan + ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Placebo / Losartan / Losartan + ISMNLosartan + ISMN / Losartan + ISMN / Losartan / ISMN / PlaceboLosartan + ISMN / Placebo / ISMN / Losartan + ISMN / LosartanPlacebo / ISMN / Losartan / Losartan + ISMN / Losartan + ISMNLosartan / Losartan + ISMN / ISMN / Placebo / Losartan + ISMNISMN / Losartan + ISMN / Losartan + ISMN / Losartan / PlaceboLosartan + ISMN / Placebo / Losartan + ISMN / ISMN / LosartanLosartan + ISMN / Losartan / Placebo / Losartan + ISMN / ISMN
Started1100100011
Completed1100100011
Not completed0000000000

Outcome measures

PrimaryMean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg

The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.

Time frame:
Baseline and 10 hours postdose
Reported as:
Least squares mean · Percent Change
Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg
Percent ChangeLosartan 100 mg + ISMN 60 mgLosartan 100 mg
Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg-24.9 ± 3.8-1.8 ± 3.8
Statistical analysis
  • Losartan 100 mg + ISMN 60 mg vs Losartan 100 mg · ANOVA · p = <0.001 (1-sided, alpha = 0.05)Fixed effects model with terms for subject, treatment and period
PrimaryMean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo

The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline.

Time frame:
Baseline and 10 hours postdose
Reported as:
Least squares mean · Percent Change
Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo
Percent ChangeLosartan 100 mg + ISMN 60 mgPlacebo
Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo-24.9 ± 3.8-1.3 ± 3.8
Statistical analysis
  • Losartan 100 mg + ISMN 60 mg vs Placebo · ANOVA · p = <0.001 (1-sided, alpha = 0.05)Fixed effects model with terms for subject, treatment and period

Adverse events

Collected over Run-in period through 14 days post last dose of study drug (documented by telephone contact or in person). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/12 (0%)1/12 (8.3%)
Losartan 100 mg—0/11 (0%)2/11 (18.2%)
Losartan 100 mg + ISMN 15 mg—0/13 (0%)1/13 (7.7%)
Losartan 100 mg + ISMN 60 mg—0/11 (0%)4/11 (36.4%)
ISMN 60 mg—0/12 (0%)4/12 (33.3%)
Most frequent other events
Most frequent other events
EventPlaceboLosartan 100 mgLosartan 100 mg + ISMN 15 mgLosartan 100 mg + ISMN 60 mgISMN 60 mg
HypotensionVascular disorders0/120/110/133/110/12
HeadacheNervous system disorders1/121/110/132/113/12
NauseaGastrointestinal disorders1/121/110/131/111/12
DizzinessNervous system disorders0/120/110/131/111/12
SomnolenceNervous system disorders0/121/110/130/110/12
Oedema PeripheralGeneral disorders0/120/111/130/110/12
Muscle SpasmsMusculoskeletal and connective tissue disorders0/120/111/130/110/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants in Study
Mean57.2 (46 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants in Study
Female7
Male6
Exclusionary Medication Washout
Exclusionary Medication Washout(participants)All Participants in Study
Yes3
No10
Diastolic Blood Pressure
Diastolic Blood Pressure(mm Hg)All Participants in Study
Mean90.6 (77 to 103)
Heart Rate
Heart Rate(Beats per Minute)All Participants in Study
Mean75.4 (48 to 99)
Systolic Blood Pressure
Systolic Blood Pressure(mm Hg)All Participants in Study
Mean141.5 (114 to 165)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kaufman R, Nunes I, Bolognese JA, Miller DL, Salotti D, McCarthy JM, Smith WB, Herman GA, Feig PU. Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure. J Am Soc Hypertens. 2010 Nov-Dec;4(6):311-8. doi: 10.1016/j.jash.2010.10.004. PubMed 21130977 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2009
First posted
Jul 22, 2009
Start
Aug 2006
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Results first posted
Jul 15, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00943852
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jul 22, 2009
Start date
Aug 2006
Primary completion
Dec 2006
Completion
Dec 2006
Results posted
Jul 15, 2010
Last update
Feb 9, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Losartan · Isosorbide mononitrate

Start the discussion